Ultragenyx Pharmaceutical (RARE) Short-term Investments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Short-term Investments data on file, last reported at $238.0 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $238.0 million, down 35.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $238.0 million (down 35.22% YoY), and the FY2025 annual result was $259.0 million, down 40.6% from the prior year.
• Short-term Investments declined to $238.0 million in Q1 2026 per RARE's latest filing, from $259.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $614.8 million in Q4 2022 and troughed at $222.7 million in Q3 2025.
• A 5-year average of $385.5 million and a median of $369.5 million in 2023 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments surged 42.12% in 2022, then plunged 52.71% in 2025.
• A 5-year view of Short-term Investments shows it stood at $614.8 million in 2022, then slumped by 40.86% to $363.6 million in 2023, then increased by 19.9% to $436.0 million in 2024, then slumped by 40.6% to $259.0 million in 2025, then retreated by 8.11% to $238.0 million in 2026.
• Business Quant data shows RARE's Short-term Investments at $238.0 million in Q1 2026, $259.0 million in Q4 2025, and $222.7 million in Q3 2025.